Reclast is manufactured by Novartis [1].
What is Reclast used for?
Reclast, also known by its generic name zoledronic acid, is a medication prescribed to treat and prevent bone loss in various conditions [2]. It is used in postmenopausal women to prevent osteoporosis, in men to treat osteoporosis, and to increase bone mass in individuals with osteoporosis [3]. Reclast is also used to treat Paget's disease of bone, a chronic disorder causing enlarged and deformed bones [4]. Additionally, it is administered to prevent skeletal complications in patients with bone metastases from solid tumors [5].
How does Reclast work?
Reclast belongs to a class of drugs called bisphosphonates [6]. It works by slowing down bone loss and increasing bone density [6]. The medication inhibits osteoclast activity, which are the cells responsible for breaking down bone tissue [7]. By reducing bone resorption, Reclast helps to maintain bone structure and strength, thereby reducing the risk of fractures [7].
When does Reclast's patent expire?
Information on specific patent expiry dates for Reclast is often proprietary and can be complex due to multiple patents covering different aspects of the drug, including formulation and manufacturing [8]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can include expiry dates and any extensions or litigation [8].
Are there alternatives to Reclast?
Several alternative medications and treatments exist for conditions treated by Reclast. For osteoporosis, alternatives include other bisphosphonates like alendronate (Fosamax) and risedronate (Actonel), as well as denosumab (Prolia), teriparatide (Forteo), and romosozumab (Evenity) [9]. For Paget's disease, other bisphosphonates are also commonly used [4]. For preventing skeletal-related events in cancer patients, options may include other bisphosphonates or denosumab [5].
What are the side effects of Reclast?
Common side effects of Reclast can include flu-like symptoms, fever, muscle pain, joint pain, headache, and fatigue [2]. Less common but serious side effects can include kidney problems, severe bone, joint, or muscle pain, and osteonecrosis of the jaw (ONJ), a condition where bone tissue in the jaw dies [2][10]. A rare but severe side effect is an atypical femur fracture, a break in the thigh bone that can occur with prolonged use [2].
What is the recommended dosage for Reclast?
The dosage and frequency of Reclast administration depend on the condition being treated [3][4][5]. It is typically given as a single intravenous infusion once a year for osteoporosis and Paget's disease, and every three to four weeks for preventing skeletal complications in cancer patients [3][4][5]. It is crucial to follow a healthcare provider's specific instructions regarding dosage and administration [3][4][5].
How long does it take for Reclast to show effects?
The effects of Reclast on bone density and fracture risk are gradual. While patients may not feel immediate changes, the medication works over time to strengthen bones [7]. Significant improvements in bone mineral density can typically be observed after a year or more of consistent treatment [7].
Who should not take Reclast?
Reclast is not suitable for everyone. Individuals with severe kidney problems, hypocalcemia (low calcium levels), or those who are pregnant or breastfeeding should not take Reclast [2]. It is important to inform a doctor about all pre-existing medical conditions before starting treatment [2].
How is Reclast administered?
Reclast is administered intravenously, meaning it is given through a needle inserted into a vein [2]. This infusion is typically performed in a doctor's office or clinic by a healthcare professional [2].
---
Sources:
[1] https://www.novartis.com/
[2] https://www.drugs.com/mtm/reclast.html
[3] https://www.nhs.uk/medicines/zoledronic-acid/
[4] https://www.mayoclinic.org/drugs-supplements/zoledronic-acid-intravenous-route/description/drg-20065531
[5] https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zoledronic-acid
[6] https://medlineplus.gov/druginfo/meds/a603024.html
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710832/
[8] https://drugpatentwatch.com/
[9] https://www.boneandjoint.org.uk/document/3736
[10] https://www.nidcr.nih.gov/health-topics/bisphosphonate-therapy-and-jaw-osteonecrosis